Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.

MLA

Rosenson, Robert S., et al. “Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.” JAMA Cardiology, vol. 8, no. 11, Nov. 2023, pp. 1070–76. EBSCOhost, https://doi.org/10.1001/jamacardio.2023.2921.

APA

Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., McGinniss, J., Gaudet, D., & Pordy, R. (2023). Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia. JAMA Cardiology, 8(11), 1070–1076. https://doi.org/10.1001/jamacardio.2023.2921

Chicago

Rosenson, Robert S., Lesley J. Burgess, Christoph F. Ebenbichler, Seth J. Baum, Erik S. G. Stroes, Shazia Ali, Nagwa Khilla, Jennifer McGinniss, Daniel Gaudet, and Robert Pordy. 2023. “Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia.” JAMA Cardiology 8 (11): 1070–76. doi:10.1001/jamacardio.2023.2921.